Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBR 830 (ISB 830) in Adults with Moderate to Severe Atopic Dermatitis
2018-000783-29Phase 2Completed
- Sponsor
- Ichnos Sciences Inc.
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing ISB 830 monotherapy with Placebo (2 arms). Primary endpoint: Percentage change from baseline in EASI score at Week 16. Started Jul 2018; status: completed.
02
Drugs
telazorlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-000783-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000783-29.